UK's NICE lays out its position on DESs: tech "not cost effective"
This article was originally published in Clinica
Executive Summary
August 28 is the short deadline by which NICE, the UK's National Institute for Health and Clinical Excellence, expects to have received comments on its draft guidance on drug-eluting stents (DESs) for the treatment of coronary artery disease. The NICE appraisal committee findings, issued on August 7 and due to be followed up by a second committee meeting on September 4, say that DESs are "not a cost-effective use of NHS resources".